STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
STAT PlusOpinionAdam’s Take FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming A public pressure campaign couldn’t alter the hard reality: The drug didn’t work Manage alerts for this article Save this story for later Share this article By Adam FeuersteinNov. 20, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology.
He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either.
Capricor conducted two randomized clinical trials. Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms. Advertisement But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease.
STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?
Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.
Subscribe Log In biotechnology, Pharmaceuticals, rare diseases, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Adam's Biotech Scorecard November 19, 2026 STAT Plus: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment Adam's Take November 17, 2026 STAT Plus: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial Advertisement Adam's Biotech Scorecard November 12, 2026 STAT Plus: What to know about Biogen’s big lupus study readout Adam's Biotech Scorecard November 12, 2026 STAT Plus: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem Adam's Biotech Scorecard November 5, 2026 STAT Plus: A closer look at ProMis Neurosciences and its Alzheimer’s drug Subscriber Picks
comments(0)
5-min edit window · permanent after that